{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Balagurunathan Y"],"pubmed_abstract":["<h4>Background</h4>Relapsed and refractory Diffuse large B cell lymphoma (DLBCL) can be successfully treated with axicabtagene ciloleucel (axi-cel), a CD19-directed autologous chimeric antigen receptor T cell (CAR-T) therapy. Diagnostic image-based features could help identify the patients who would clinically respond to this advanced immunotherapy.<h4>Purpose</h4>The aim of this study was to establish a radiomic image feature-based signature derived from positron emission tomography/computed tomography (PET/CT), including metabolic tumor burden, which can predict a durable response to CAR-T therapy in refractory/relapsed DLBCL.<h4>Methods</h4>We conducted a retrospective review of 155 patients with relapsed/refractory DLBCL treated with axi-cel CAR-T therapy. The patients' disease involve"],"journal":["Frontiers in oncology"],"pagination":["1485039"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11629080"],"repository":["biostudies-literature"],"pubmed_title":["Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy."],"pmcid":["PMC11629080"],"pubmed_authors":["Mattie M","Locke FL","Qi J","Kim JJ","Jain M","Choi JW","Wei Z","Balagurunathan Y","Dean E","Lu H","Thompson Z","Vardhanabhuti S","Corallo S"],"additional_accession":[]},"is_claimable":false,"name":"Radiomic features of PET/CT imaging of large B cell lymphoma lesions predicts CAR T cell therapy efficacy.","description":"<h4>Background</h4>Relapsed and refractory Diffuse large B cell lymphoma (DLBCL) can be successfully treated with axicabtagene ciloleucel (axi-cel), a CD19-directed autologous chimeric antigen receptor T cell (CAR-T) therapy. Diagnostic image-based features could help identify the patients who would clinically respond to this advanced immunotherapy.<h4>Purpose</h4>The aim of this study was to establish a radiomic image feature-based signature derived from positron emission tomography/computed tomography (PET/CT), including metabolic tumor burden, which can predict a durable response to CAR-T therapy in refractory/relapsed DLBCL.<h4>Methods</h4>We conducted a retrospective review of 155 patients with relapsed/refractory DLBCL treated with axi-cel CAR-T therapy. The patients' disease involve","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2025-04-26T23:16:11.997Z","creation":"2025-04-06T17:32:05.146Z"},"accession":"S-EPMC11629080","cross_references":{"pubmed":["39659779"],"doi":["10.3389/fonc.2024.1485039"]}}